[1]尹小芳,叶祖科,汤秀容,等.玻璃体内注射雷珠单抗后视网膜分支静脉阻塞性黄斑水肿复发的危险因素分析[J].眼科新进展,2020,40(1):046-49.[doi:10.13389/j.cnki.rao.2020.0011]
 YIN Xiaofang,YE Zuke,TANG Xiurong,et al.Risk factors for recurrence of macular edema associated with branch retinal vein occlusions after intravitreal injection of Ranibizumab treatment[J].Recent Advances in Ophthalmology,2020,40(1):046-49.[doi:10.13389/j.cnki.rao.2020.0011]
点击复制

玻璃体内注射雷珠单抗后视网膜分支静脉阻塞性黄斑水肿复发的危险因素分析/HTML
分享到:

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
40卷
期数:
2020年1期
页码:
046-49
栏目:
应用研究
出版日期:
2020-01-05

文章信息/Info

Title:
Risk factors for recurrence of macular edema associated with branch retinal vein occlusions after intravitreal injection of Ranibizumab treatment
文章编号:
20200111
作者:
尹小芳叶祖科汤秀容梁影影黎彦豪罗书科卢彦
528000 广东省佛山市,佛山市第二人民医院眼科研究所
Author(s):
YIN XiaofangYE ZukeTANG XiurongLIANG YingyingLI YanhaoLUO ShukeLU Yan
Institute of Ophthalmology,the Second People’s Hospital of Foshan,Foshan 528000,Guangdong Province,China
Corresponding author:LU Yan,E-mail:837800105@qq.com
关键词:
雷珠单抗视网膜分支静脉阻塞黄斑水肿
Keywords:
Ranibizumabbranch retinal vein occlusionmacular edema
分类号:
R774
DOI:
10.13389/j.cnki.rao.2020.0011
文献标志码:
A
摘要:
目的 探讨玻璃体内注射雷珠单抗后视网膜分支静脉阻塞(branch retinal vein occlusion,BRVO)性黄斑水肿复发的危险因素。方法 回顾性分析2013年1月至2018年1月在我院行玻璃体内注射雷珠单抗治疗BRVO性黄斑水肿患者的临床资料,记录患者的性别、年龄、眼别及术前的最佳矫正视力、眼压、病程、阻塞支分布情况、有无高血压病史、术前脉压差、术前黄斑中心凹厚度(central macular thickness,CMT)、有无联合视网膜激光光凝治疗,根据注射雷珠单抗的次数将患者分为单次注射组和复发组,比较两组之间术前基线资料的差异,运用Logistic回归分析探讨黄斑水肿复发的相关危险因素。结果 114例(114眼)纳入研究,其中单次注射组79例,复发组35例,两组相比,复发组的年龄、基线CMT均显著大于单次注射组(均为P<0.05),其余指标两组间相比差异均无统计学意义(均为P>0.05)。Logistic回归分析结果显示,年龄、基线CMT是玻璃体内注射雷珠单抗后BRVO性黄斑水肿复发的危险因素(年龄:OR=1.080,P=0.01;CMT:OR=1.005,P<0.01)。结论 年龄和基线CMT是黄斑水肿复发的主要危险因素,年龄越大、基线CMT越高的患者需重复注射雷珠单抗的风险越高。
Abstract:
Objective To investigate the risk factors for recurrence of macular edema associated with branch retinal vein occlusions (BRVO) after intravitreal injection of Ranibizumab.Methods The study collected the clinical cases diagnosed with macular edema associated with BRVO and treated with intravitreal injection of Ranibizumab in our department from January 2013 to January 2018.Relevant data were retrospective analyzed,such as gender,age,eye side,preoperative best corrected visual acuity (BCVA),intraocular pressure (IOP),duration,occlusion branch,hypertension history,preoperative blood pressure,preoperative central macular thickness (CMT) and laser treatment history (combined therapy of retinal laser photocoagulation or not).All patients were divided into single injection group and recurrence group based on the injection frequency.The differences of baseline information were compared between the two groups.Logistic regression analysis was performed to investigate the risk factors for recurrence of macular edema.Results There were 114 patients(114 eyes) in this study,including 79 patients in single injection group and 35 patients in recurrence group.Age and baseline CMT in recurrence group were obviously higher than those in single injection group,and statistical differences were observed (all P<0.05).Logistic regression analysis showed that age and CMT were risk factors for the recurrence of macular edema associated with BRVO after intravitreal injection of Ranibizumab (OR=1.08,P=0.01 for age;OR=1.005,P<0.01 for CMT).Conclusion Age and baseline CMT are risk factors for the recurrence of macular edema,the older the patient is and the higher the baseline CMT,the more risk for repeat intravitreal injection of Ranibizumab.

参考文献/References:

[1] MIWA Y,MURAOKA Y,OSAKA R,OOTO S,MURAKAMI T,SUZUMA K,et al.Ranibizumab for macular edema after branch retinal vein occlusion:one initial injection versus three monthly injections[J].Retina,2017,37(4):702-709.
[2] UNSAL E,ELTUTAR K,SULTAN P,GUNQEL H.Efficacy and safety of Pro Re Nata regimen without loading dose ranibizumab injections in retinal vein occlusion[J].Pak J Med Sci,2015,31(3):510-515.
[3] PIELEN A,FELTGEN N,ISSERSTEDT C,CALLIZO J,JUNKER B,SCHMUCKER C.Efficacy and safety of intravitreal therapy in macular edema due to branch and central retinal vein occlusion:a systematic review[J].PLoS One,2013,8(10):e78538.
[4] ROGERS S L,MCINTOSH R L,LIM L,MITCHELL P,CHEUNG N,KOWALSKI J W,et al.Natural history of branch retinal vein occlusion:an evidence-based systematic review[J].Ophthalmology,2010,117(6):1094-1101.
[5] AIELLO L P,AVERY R L,ARRIGG P G,KEYT B A,JAMPEL H D,SHAH S T,et al.Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders[J].N Engl J Med,1994,331:1480-1487.
[6] 李玉茹.小剂量曲安奈德玻璃体腔注射治疗静脉阻塞黄斑水肿疗效观察[J].新乡医学院学报,2016,33(8):695-697.
LI Y R.Curative effect of small doses of triamcinolone acetonide in vitreous body cavity injection treatment on retinal vein occlusion macular edema[J].J Xinxiang Med Univ,2016,33(8):695-697.
[7] KONDO M,KONDO N,ITO Y,KACHI S,KIKUCHI M,YASUMA T R,et al.Intravitreal injection of bevacizumab for macular edema secondary to branch retinal vein occlusion:results after 12 months and multiple regression analysis[J].Retina,2009,29(9):1242-1248.
[8] AHN S J,AHN J,WOO S J,PARK K H.Initial dose of three monthly intravitreal injections versus PRN intravitreal injections of bevacizumab for macular edema secondary to branch retinal vein occlusion[J].Biomed Res Int,2013,2013:209735.
[9] HIGASHIYAMA T,SAWADA O,KAKINOKI M,SAWADA T,KAWAMURA H,OHJI M.Prospective comparisons of intravitreal injections of triamcinolone acetonide and bevacizumab for macular oedema due to branch retinal vein occlusion[J].Acta Ophthalmol,2013,91(4):318-324.
[10] HIKICHI T,HIGUCHI M,MATSUSHITA T,KOSAKA S,MATSUSHITA R,TAKAMI K.Two-year outcomes of intravitreal bevacizumab therapy for macular oedema secondary to branch retinal vein occlusion[J].Br J Ophthalmol,2014,98(2):195-199.
[11] SMIDDY W E.Economic considerations of macular edema therapies[J].Ophthalmology,2011,118(9):1827-1833.
[12] TAYLOR M,SERBETCI E,FERREIRA A,GAIRY K,LEWIS L,BLOUIN J,et al.A United Kingdom-based economic evaluation of ranibizumab for patients with retinal vein occlusion (RVO)[J].J Med Econ,2014,17(6):423-434.
[13] YOO J H,AHN J,OH J,CHA J,KIM S W.Risk factors of recurrence of macular oedema associated with branch retinal vein occlusion after intravitreal bevacizumab injection[J].Br J Ophthalmol,2017,101(10):1334-1339.
[14] NOMA H,MINAMOTO A,FUNATSU H,TSUKAMOTO H,NAKANO K,YAMASHITA H,et al.Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion[J].Graefes Arch Clin Exp Ophthalmol,2006,244(3):309-315.
[15] NOMA H,FUNATSU H,YAMASAKI M,TSUKAMOTO H,MIMURA T,SONE T,et al.Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6[J].Am J Ophthalmol,2005,140(2):256-261.
[16] NOMA H,FUNATSU H,MIMURA T,HORI S.Changes of vascular endothelial growth factor after vitrectomy for macular edema secondary to retinal vein occlusion[J].Eur J Ophthalmol,2008,18(6):1017-1019.
[17] NOMA H,MIMURA T,YASUDA K,NAKAGAWA H,MOTO-HASHI R,KOTAKE O,et al.Cytokines and recurrence of macular edema after intravitreal ranibizumab in patients with branch retinal vein occlusion[J].Ophthalmologica,2016,236(4):228-234.
[18] YAMADA R,NISHIDA A,SHIMOZONO M,KAMEDA T,MIYAMOTO N,MANDAI M,et al.Predictive factors for recurrence of macular edema after successful intravitreal bevacizumab therapy in branch retinal vein occlusion[J].Jpn J Ophthalmol,2015,59(6):389-393.
[19] 何海燕.康柏西普治疗视网膜静脉阻塞性黄斑囊样水肿的复发研究[D].汕头:汕头大学,2016.
HE H Y.The recurrence of cystiod macular edema due to retinal vein occlusion treated with conbercept[D].Shantou:Shantou University,2016.
[20] HAYASHI A,YUNOKI T,MIYAKOSHI A,MITARAI K,FUJINO T,YANAGISAWA S.Intravitreal injection of bevacizumab combined with macular grid laser photocoagulation for macular edema in branch retinal vein occlusion[J].Jpn J Ophthalmol,2011,55(6):625-631.
[21] DONATI S,BAROSI P,BIANCHI M,OUM M,AZZOLINI C.Combined intravitreal bevacizumab and grid laser photocoagulation for macular edema secondary to branch retinal vein occlusion[J].Eur J Ophthalmol,2012,22(4):607-614.

相似文献/References:

[1]李姣 王兴荣 崔彦 刘正峰 王影 李洋.雷珠单抗选择性体外抑制睫状体恶性黑色素瘤[J].眼科新进展,2013,33(11):000.
[2]张祺 冯劼 李培凤 金翼.Lucentis联合氪黄激光治疗视网膜分支静脉阻塞黄斑水肿的疗效观察[J].眼科新进展,2013,33(12):000.
[3]曹婷婷,陈桂芬,范玉香,等.视网膜分支静脉阻塞合并黄斑水肿不同治疗方法的疗效观察[J].眼科新进展,2014,34(8):772.[doi:10.13389/j.cnki.rao.2014.0213]
 CAO Ting-Ting,CHEN Gui-Fen,FAN Yu-Xiang,et al.Clinical observation in different treatment methods of branch retinal vein occlusion[J].Recent Advances in Ophthalmology,2014,34(1):772.[doi:10.13389/j.cnki.rao.2014.0213]
[4]金昱,石安娜,刘淼. 玻璃体内注射雷珠单抗(Ranibizumab)治疗视网膜静脉阻塞继发黄斑水肿[J].眼科新进展,2014,34(9):855.[doi:10.13389/j.cnki.rao.2014.0236]
[5]张聪,刘东宁,徐丽. 玻璃体内注射Lucentis治疗中心性渗出性脉络膜视网膜病变的临床疗效[J].眼科新进展,2014,34(9):864.[doi:10.13389/j.cnki.rao.2014.0239]
[6]章晖,叶波,邱新文,等.雷珠单抗辅助23G玻璃体切割术治疗增生性糖尿病视网膜病变[J].眼科新进展,2014,34(10):975.[doi:10.13389/j.cnki.rao.2014.0270]
[7]王博,吴京,马明,等. 玻璃体内注射雷珠单抗与曲安奈德治疗糖尿病黄斑水肿的疗效对比分析[J].眼科新进展,2015,35(3):246.[doi:10.13389/j.cnki.rao.2015.0066]
 WANG Bo,WU Jing,MA Ming,et al. Clinictid effect comparison of intravitreal lucentis and triamcinolone acetonide for diabetic macular edema[J].Recent Advances in Ophthalmology,2015,35(1):246.[doi:10.13389/j.cnki.rao.2015.0066]
[8]刘斌,杨玉霞,刘杏,等. 雷珠单抗联合Ahmed青光眼阀植入术治疗新生血管性青光眼[J].眼科新进展,2015,35(3):263.[doi:10.13389/j.cnki.rao.2015.0070]
 LIU Bin,YANG Yu-Xia,LIU Xing,et al. Intravitreal lucentis injection combined with Ahmed valve implantation for neovascular glaucoma[J].Recent Advances in Ophthalmology,2015,35(1):263.[doi:10.13389/j.cnki.rao.2015.0070]
[9]傅维娜,陈梅珠,王云鹏. Lucentis联合视网膜光凝治疗视网膜分支静脉阻塞继发黄斑水肿[J].眼科新进展,2015,35(3):270.[doi:10.13389/j.cnki.rao.2015.0072]
 FU Wei-Na,CHEN Mei-Zhu,WANG Yun-Peng. Intravitreal injection with lucentis combined with local retinal photocoagulation for macular edema secondary to branch retinal vein occlusion[J].Recent Advances in Ophthalmology,2015,35(1):270.[doi:10.13389/j.cnki.rao.2015.0072]
[10]刘志南,邓国华,江一. 光凝前雷珠单抗玻璃体内注射对CNV患者黄斑区视网膜及视功能的影响[J].眼科新进展,2015,35(4):365.[doi:10.13389/j.cnki.rao.2015.0098]
 LIU Zhi-Nan,DENG Guo-Hua,JIANG Yi. Effects of ranibizumab intravitreal injection before photocoagulation on macular retina and visual function in patients with CNV[J].Recent Advances in Ophthalmology,2015,35(1):365.[doi:10.13389/j.cnki.rao.2015.0098]
[11]李仕永,高瑞莹,陈晖.雷珠单抗联合氩激光视网膜光凝治疗不同时期的视网膜分支静脉阻塞所致黄斑水肿的疗效[J].眼科新进展,2016,36(12):1161.[doi:10.13389/j.cnki.rao.2016.0309]
 LI Shi-Yong,GAO Rui-Ying,CHEN Hui.Effects of ranibizumab ( Lucentis) intravitreal injection combined with retinal argon laser photocoagulation on macular edema secondary to different period of branch retinal vein occlusion[J].Recent Advances in Ophthalmology,2016,36(1):1161.[doi:10.13389/j.cnki.rao.2016.0309]
[12]江慧娟,庞东渤.视网膜光凝联合玻璃体内注射雷珠单抗治疗缺血型视网膜分支静脉阻塞(BRVO)致黄斑水肿的疗效[J].眼科新进展,2018,38(4):348.[doi:10.13389/j.cnki.rao.2018.0081]
 JIANG Hui-Juan,PANG Dong-Bo.Efficacy of intravitreal ranibizumab combined with laser photocoagulation for the treatment of macular edema induced by ischemic branch retinal vein occlusion[J].Recent Advances in Ophthalmology,2018,38(1):348.[doi:10.13389/j.cnki.rao.2018.0081]
[13]杨大勇,李琳.雷珠单抗联合激光光凝术治疗视网膜分支静脉阻塞(BRVO)继发黄斑水肿疗效观察[J].眼科新进展,2019,39(4):369.[doi:10.13389/j.cnki.rao.2019.0084]
 YANG Da-Yong,LI Lin.Ranibizumab combined with laser photocoagulation in the treatment of patients with macular edema secondary to branch retinal vein occlusion[J].Recent Advances in Ophthalmology,2019,39(1):369.[doi:10.13389/j.cnki.rao.2019.0084]
[14]马恒哲.雷珠单抗对视网膜分支静脉阻塞继发黄斑水肿患者视网膜血流密度的影响[J].眼科新进展,2021,41(9):874.[doi:10.13389/j.cnki.rao.2021.0183]
 MA Hengzhe.Effect of ranibizumab on the density of retinal blood flow in patients with macular edema secondary to branch retinal vein occlusion[J].Recent Advances in Ophthalmology,2021,41(1):874.[doi:10.13389/j.cnki.rao.2021.0183]
[15]白小芳,赵芃芃,秦梅,等.雷珠单抗联合Ozurdex治疗视网膜分支静脉阻塞继发黄斑水肿的疗效观察[J].眼科新进展,2022,42(5):394.[doi:10.13389/j.cnki.rao.2022.0080]
 BAI Xiaofang,ZHAO Pengpeng,QIN Mei,et al.Clinical effect of Ranibizumab combined with Ozurdex in the treatment of macular edema secondary to branch retinal vein occlusion[J].Recent Advances in Ophthalmology,2022,42(1):394.[doi:10.13389/j.cnki.rao.2022.0080]

备注/Memo

备注/Memo:
佛山市医学科研项目(编号:20190116);广东省中医药局科研立项课题(编号:20162134);佛山市科技计划项目(编号:2016AB001731);佛山市国家卫计委级医学重点专科培育项目(编号:Fspy1-2015005)
更新日期/Last Update: 2020-01-05